期刊文献+

应用基准剂量法探讨砷、镉接触人群肾功能损害危险性评价 被引量:10

Calculation of the combined renal dysfunction risk in patients co exposed to arsenicum and cadmium by using benchmark dose method
原文传递
导出
摘要 目的研究砷接触人群肾功能损害情况,探讨镉在砷接触人群肾功能损害方面与砷的联合作用。方法以贵州省地方病办公室1991年3月确诊并经1997年3月和2001年3月临床复查的122例砷中毒患者为本次调查对象,无砷污染区居民123名作为对照。以尿砷、尿镉作为接触标志物,尿β2微球蛋白(Uβ2MG)、尿白蛋白、尿N乙酰βD氨基葡萄糖苷酶(UNAG)作为砷、镉致肾小管和肾小球损害的效应标志物。同时分别计算尿砷、尿镉的基准剂量(BMD)及其下限值(BMDL)。结果接触组的接触指标和效应指标均高于对照组,尿砷、尿镉水平与Uβ2MG、尿白蛋白、UNAG水平间均为正相关,具有明显的剂量效应关系;砷、镉联合毒性比单独砷或镉同等剂量下的毒性更大。尿砷的BMD和BMDL值(以肌酐含量计)分别为12191~17188μg/g和10211~14444μg/g;尿镉的BMD和BMDL值(以肌酐含量计)分别为105~148μg/g和088~124μg/g。结论砷、镉联合毒性剂量明显低于单一毒性剂量,镉可能增强了砷在长期砷接触人群中对肾脏的损伤作用;运用BMD方法计算砷接触人群肾功能损伤尿砷、尿镉的BMD和BMDL值,尿砷、尿镉的BMDL值分别为以肌酐含量计10211μg/g、088μg/g。 Objective To research the impairment of renal function and the combined effects of arsenic and cadmium exposure in population residing in polluted area,and to calculate the benchmark doses of urinary arsenic (UAs) and cadmium (UCd) in renal dysfunction Methods The concentrations of Uas and UCd were used as as exposure biomarker Urinary β 2 microglobulin (Uβ 2 MG), N acetyl β glucosaminidase (UNAG), and albumin were calculated as biomarkers of renal dysfunction The benchmark dose (BMD) and the lower confidence limit of the benchmark dose (BMDL) were calculated Totally 245 patients were enrolled in the study, them,of 122 were from the exposed area, and 123 from the control area Results UAs and UCd concentrations in the exposed group were shown significantly higher than those in the control group ( P <0 01) The levels of Uβ 2 MG, UNAG and urinary albumin in the exposed group were significantly higher than those of the controls ( P <0 01) There exsted positive correlation among the concentrations of UAs, UCd, Uβ 2 MG, urinary albumin and UNAG,showing a significant dose effect relationship The combination of cadmium and arsenic caused even more renal injury than by chemicals alone in a same dose The BMD/BMDL of UAs were estimated as 121 91 171 88 μg/g Cr and 102 11 144 44 μg/g Cr Of UCd ,the BMD/BMDL were 1 05 1 48 μg/g Cr and 0 88 1 24 μg/g Cr Conclusions This study indicates the combination of cadmium and arsenic might cause even more renal injury than by chemicals given alone, and cadmium might cause potential arsenic nephrotoxicity during long term coexposure to arsenic and cadmium in human beings It also suggests that UAs and UCd should be kept below 102 11 and 0 88 μg/g creatinine as to preventingrenal damage from coexposure to arsenic and cadmium The BMD method should be used in calculating the BMD of UAs and UCd on renal dysfunction
出处 《中华预防医学杂志》 CAS CSCD 北大核心 2004年第6期374-378,共5页 Chinese Journal of Preventive Medicine
基金 国家自然科学基金资助项目(30060077) 欧共体INCO-DC项目基金资助项目(ERB3514PL971430)
关键词 基准剂量法 接触人群 肾功能损害 危险性评价 Arsenic Cadmium Urinalysis Risk assessment
  • 相关文献

参考文献10

  • 1Cassee FR, Groten JP, van Bladeren PJ, et al. Toxicological evaluation and risk assessment of chemical mixtures. Crit Rev Toxicol, 1998, 28: 73-101.
  • 2Sexton K, Beck BD, Bingham E, et al. Chemical mixtures from a public health perspective: the importance of research for informed decision making. Toxicology, 1995, 105: 429-441.
  • 3Nordberg GF, Piscator M, Lind B. Distribution of cadmium among protein fractions of mouse liver. Acta Pharmacol Toxcicol, 1971, 29:456-470.
  • 4Nixon DE,Mussmann GV,Eckdahl SJ,et al. Total arsenic in urine: Palladium-persulfate vs nickel as a matrix modifier for graphite furnace atomic absorption spectrophotometry. Clin Chem, 1991, 37:1575-1579.
  • 5Hare RS. Endogenenous Creatinine Serum and urine . Proc Soc Exp Biol, 1950, 74:148.
  • 6World Health Organization. Environmental Health Criteria. V134:Cadmium. Geneva: WHO, 1992. 3-205.
  • 7World Health Organization. Environmental Health Criteria. V224:Arsenic and Arsenic Compounds.2nd ed.Geneva: WHO, 2001. 7-388.
  • 8Buchet J P, Lauwerys R, Roels H. Renal effects of cadmium body burden of the general population. Lancet, 1990, 2: 699-702.
  • 9Elinder CG, Edling C, Lindberg E,et al. Assessment of renal function in workers previously exposed to cadmium. Br J Ind Med, 1985, 42: 754 -760.
  • 10Gaylor D, Ryan L, Krewski D, et al. Procedures for calculating benchmark doses for health risk assessment. Regul Toxicol Pharmarcol, 1998, 28: 150-164.

共引文献1

同被引文献96

引证文献10

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部